VX765, a Specific Caspase-1 Inhibitor, Alleviates Lung Ischemia Reperfusion Injury by Suppressing Endothelial Pyroptosis and Barrier Dysfunction.
VX765, a Specific Caspase-1 Inhibitor, Alleviates Lung Ischemia Reperfusion Injury by Suppressing Endothelial Pyroptosis and Barrier Dysfunction.
复制标题
VX765 是一种特异性 Caspase-1 抑制剂,通过抑制内皮焦亡和屏障功能障碍减轻肺缺血再灌注损伤
DOI:
10.1155/2021/4525988
复制
发表时间:
2021
影响因子:
--
通讯作者:
Lin F
中科院分区:
文献类型:
--
作者:
Wu S;Li Z;Ye M;Liu C;Liu H;He X;Qin Y;Liang F;Pan L;Lin F
Lung ischemia reperfusion injury (LIRI) is a complex pathophysiological process with high morbidity and mortality. An important pathophysiological characteristic of LIRI is endothelial barrier dysfunction, although the mechanism involved in this process remains unclear. VX765, a specific caspase-1 inhibitor, has been shown to have a protective effect against several diseases including sepsis, atherosclerosis, and glial inflammatory disease. The objective of this study was to determine whether VX765 had a protective effect in LIRI. The results showed that lung ischemia/reperfusion (I/R) and oxygen/glucose deprivation and reoxygenation (OGD/R) induced endothelial pyroptosis and barrier dysfunction characterized by an inflammatory response. Treatment with VX765 successfully alleviated I/R- and OGD/R-induced endothelial pyroptosis and barrier dysfunction by inhibiting caspase-1 in vivo and in vitro. In conclusion, these findings showed that VX765 provided effective protection against lung I/R-induced endothelial pyroptosis and barrier dysfunction.
登录
查看更多内容
影响因子:
4.6
作者:
Haihua C;Wei W;Kun H;Yuanli L;Fei L
通讯作者:
Fei L
影响因子:
25.7
作者:
Gaul S;Leszczynska A;Alegre F;Kaufmann B;Johnson CD;Adams LA;Wree A;Damm G;Seehofer D;Calvente CJ;Povero D;Kisseleva T;Eguchi A;McGeough MD;Hoffman HM;Pelegrin P;Laufs U;Feldstein AE
通讯作者:
Feldstein AE
影响因子:
11.4
作者:
Jia, Yifan;Cui, Ruixia;Zhang, Jingyao
通讯作者:
Zhang, Jingyao
影响因子:
12.4
作者:
Wan, Peixing;Su, Wenru;Zhuo, Yehong
通讯作者:
Zhuo, Yehong
影响因子:
19.6
作者:
Miao, Naijun;Yin, Fan;Lu, Limin
通讯作者:
Lu, Limin